.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Novartis
McKesson
Boehringer Ingelheim
US Army
Deloitte
Argus Health
Express Scripts
UBS
Daiichi Sankyo

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 050779

« Back to Dashboard
NDA 050779 describes CEFAZOLIN AND DEXTROSE, which is a drug marketed by B Braun and is included in one NDA. It is available from one supplier. Additional details are available on the CEFAZOLIN AND DEXTROSE profile page.

The generic ingredient in CEFAZOLIN AND DEXTROSE is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.

Summary for NDA: 050779

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 050779

Ingredient-typeCephalosporins

Suppliers and Packaging for NDA: 050779

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEFAZOLIN AND DEXTROSE
cefazolin sodium
INJECTABLE;INJECTION 050779 NDA B. Braun Medical Inc. 0264-3103 0264-3103-11 24 CONTAINER in 1 CASE (0264-3103-11) > 50 mL in 1 CONTAINER
CEFAZOLIN AND DEXTROSE
cefazolin sodium
INJECTABLE;INJECTION 050779 NDA B. Braun Medical Inc. 0264-3105 0264-3105-11 24 CONTAINER in 1 CASE (0264-3105-11) > 50 mL in 1 CONTAINER

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 500MG BASE/VIAL
Approval Date:Jul 27, 2000TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 1GM BASE/VIAL
Approval Date:Jul 27, 2000TE:RLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrengthEQ 2GM BASE/VIAL
Approval Date:Jan 13, 2012TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Accenture
Fish and Richardson
Novartis
Cipla
Covington
McKesson
Mallinckrodt
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot